Brief: Brain First Development Phase For Novel Genome Editing Tool Completed (CRISPR Cas)
May 6 (Reuters) - BRAIN BIOTECH AG BNNn.DE :
* FIRST DEVELOPMENT PHASE FOR A NOVEL GENOME EDITING TOOL
COMPLETED (CRISPR CAS)
* SUCCESSFULLY COMPLETED FIRST DEVELOPMENT PHASE FOR A NOVEL
GENOME EDITING TOOL BASED ON A NON-CAS9 NUCLEASE
Source text for Eikon: ID:nEQ5M5Nksa
Further company coverage: BNNn.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))
Recent news on BRAIN Biotech AG
See all newsBrief: BRAIN Biotech 9M EBITDA EUR -1.6 Million
CEOs Lukas Linnig And Michael Krohn To Leave Co
Brief: Brain Biotech Signs Exclusive Pharma Licensing Agreement With Akribion For Up To EUR 92.3 Million Milestone Fees Plus Royalties
Brief: BRAIN Biotech 9M Adj. EBITDA at EUR -1.2 Million
Europe Research Roundup: AB Foods, Bunzl, Barratt